Concurrent pityriasis rosea and Bell's palsy

BMJ Case Reports

Volumn 2017, Issue , 2017, Pages

  Voss, Vanessa ^a   Mattox, Adam ^b   Guo, Mary ^b  

^a SAINT LOUIS UNIVERSITY   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CORTICOSTEROID; HYDROCORTISONE; PREDNISONE; ANTIVIRUS AGENT; GLUCOCORTICOID;

ANAMNESIS; ARTICLE; BELL PALSY; CASE REPORT; CHILD; DIFFERENTIAL DIAGNOSIS; DRUG TREATMENT FAILURE; FACIAL NERVE PARALYSIS; FEMALE; HERPES ZOSTER; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; MEDICAL EXAMINATION; PAPULE; PHYSICAL EXAMINATION; PITYRIASIS ROSEA; RISK FACTOR; SCHOOL CHILD; SKIN MANIFESTATION; TREATMENT RESPONSE; COMPLICATION; ROSEOLOVIRUS INFECTIONS; VIROLOGY;

ACYCLOVIR; ANTIVIRAL AGENTS; BELL PALSY; CHILD; FEMALE; GLUCOCORTICOIDS; HERPESVIRUS 6, HUMAN; HERPESVIRUS 7, HUMAN; HUMANS; PITYRIASIS ROSEA; PREDNISONE; ROSEOLOVIRUS INFECTIONS;

EID: 85010297322     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2016-218069     Document Type: Article

References (18)

1. Chuang TY, Listrup DM, Perry HO, et al. Pityriasis rosea in Rochester, Minnesota, 1969 to 1978. J Am Acad Dermatol 1982;7:80-9.
2. Chuh AA, Molinari N, Sciallis G, et al. Temporal case clustering in pityriasis rosea: a regression analysis on 1379 patients in Minnesota, Kuwait, Diyarbakir, Turkey. Arch Dermatol 2005;141:767-71.
3. Drago F, Broccolo F, Rebora A. Pityriasis rosea: an update with a critical appraisal of its possible herpesviral etiology. J Am Acad Dermatol 2009;61:303-18.
4. Chuh A, Lee A, Zawar V, et al. Pityriasis rosea-an update. Indian J Dermatol Venereol Leprol 2005;71:311-15.
5. Rebora A, Drago F, Broccolo F. Pityriasis rosea, herpesviruses: facts, controversies. Clin Dermatol 2010;28:497-501.
6. Watanabe T, Kawamura T, Jacob SE, et al. Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7, human herpesvirus-6. J Invest Dermatol 2002;119:793-7.
7. Broccolo F, Drago F, Careddu AM, et al. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6,-7. J Invest Dermatol 2005;124:1234-40.
8. Morris AM, Deeks SL, Hill MD, et al. Annualized incidence, spectrum of illness from an outbreak investigation of Bell's palsy. Neuroepidemiology 2002;21:255-61.
9. Lazarini PR, Vianna MF, Alcantara MP, et al. Herpes simplex virus in the saliva of peripheral Bell's palsy patients. Braz J Otorhinolaryngol 2006;72:7-11.
10. Abiko Y, Ikeda M, Hondo R. Secretion, dynamics of herpes simplex virus in tears, saliva of patients with Bell's palsy. Otol Neurotol 2002;23:779-83.
11. Glass GE, Tzafetta K. Bell's Palsy: a summary of current evidence, referral algorithm. Fam Pract 2014;31:631-42.
12. Turriziani O, Falasca F, Maida P, et al. Early collection of saliva specimens from Bell's palsy patients: quantitative analysis of HHV-6, HSV-1, VZV. J Med Virol 2014;86:1752-8.
13. Gronseth GS, Paduga R. Evidence-based guideline update: steroids, antivirals for Bell palsy: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012;79:2209-13.
14. Arican P, Dundar NO, Gencpinar P, et al. Efficacy of low-dose corticosteroid therapy versus high-dose corticosteroid therapy in bell's palsy in children. J Child Neurol 2016; [Epub ahead of print].
15. Sullivan F, Daly F, Gagyor I. Antiviral agents added to corticosteroids for early treatment of adults with acute idiopathic facial nerve paralysis (Bell Palsy). JAMA 2016;316:874-5.
16. Chuh A, Zawar V, Sciallis G, et al. A position statement on the management of patients with pityriasis rosea. J Eur Acad Dermatol Venereol 2016;30:1670-81.
17. Drago F, Ciccarese G, Rebora A, et al. Pityriasis rosea: a comprehensive classification. Dermatology 2016;232:431-7.
18. Drago F, Ciccarese G, Broccolo F, et al. Pityriasis rosea in children: clinical features, laboratory investigations. Dermatology 2015;231:9-14.